CDw17 antibody

Catalog No. ABIN6296201

Product Details

Target: CDw17

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Flow Cytometry (FACS), Immunofluorescence (IF)

Purpose: Mouse anti-Human CDw17 Antibody [Sodium Azide Free]

Specificity: Cell surface

Purification: Beta-2 Microglobulin associated proteins from a detergent lysate of human PBLs were used as the immunogen for the CDw17 antibody.

Immunogen: Beta-2 Microglobulin associated proteins from a detergent lysate of human PBLs were used as the immunogen for the CDw17 antibody.

Application Details

Application Notes: Flow Cytometry: 0.5-1 μg/million cells in 0.1ml
Immunofluorescence: 0.5-1 μg/mL

Restrictions: For Research Use only

Handling

Buffer: In 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: 2-8°C. The azide-free format should be aliquoted and stored at -20°C or colder.

Target Details

Target: CDw17

Background:

Target Description: CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. TNFa-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization.